(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Aldeyra Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALDX's revenue for 2024 to be $5,889,576,800, with the lowest ALDX revenue forecast at $5,889,576,800, and the highest ALDX revenue forecast at $5,889,576,800. On average, 3 Wall Street analysts forecast ALDX's revenue for 2025 to be $2,097,454,986, with the lowest ALDX revenue forecast at $1,101,350,862, and the highest ALDX revenue forecast at $3,963,685,186.
In 2026, ALDX is forecast to generate $2,918,049,721 in revenue, with the lowest revenue forecast at $2,567,855,485 and the highest revenue forecast at $3,129,721,112.